Category: GeoVax Recent News

ATLANTA, GA, January 6, 2025 GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that David Dodd, Chief Executive Officer, will review 2024 progress in a presentation at the Biotech Showcase coinciding with the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, January 13-16, 2025. Presentation…

Adds to Growing Portfolio of Intellectual Property Assets   ATLANTA, GA, December 9, 2024 — GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for Patent Application No. 17/876,682  to GeoVax, titled “Vaccinia Viral…

ATLANTA, GA, November 26, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that its Chairman & CEO, David Dodd, will present at NobleCon20 – the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference taking place December 2-5, 2024 in Boca Raton, FL. Presentation…

GEO-CM04S1 Improved Immune Response vs mRNA Vaccine   ATLANTA, GA, November 19, 2024 — GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the completion of an interim data review by the Data Safety Monitoring Board (DSMB) for the ongoing Phase 2 clinical trial of GEO-CM04S1,…

Progress in GEO-CM04S1 BARDA/Project NextGen Phase 2b trial; multiple data readouts of existing COVID-19 vaccine Phase 2 trials expected during fourth quarter 2024  Gedeptin® on track to advance into Phase 2 clinical trial for first recurrent head and neck cancer in the first half of 2025  GEO-MVA Mpox vaccine advancing with cGMP clinical batch anticipated during…

GeoVax to Host Conference Call at 4:30 PM ET   Atlanta, GA, November 5, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it will report third quarter 2024 financial results on Tuesday, November 12, 2024, after the close of U.S. markets. Following…

ATLANTA, GA, October 2, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that its Chairman & CEO, David Dodd, will participate in a panel discussion on innovative therapies for solid tumors at the 3rd Annual ROTH Healthcare Opportunities Conference taking place on October 9, 2024…

Atlanta, GA, August 28, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it has entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 975,610 shares of the Company’s common stock (or common…

Company to provide a detailed overview of Mpox including commentary on the rapid spread and methods for control, treatment, and prevention   Atlanta, GA, August 21, 2024 – GeoVax Lab, Inc. (Nasdaq: GOVX) (“GeoVax Labs” or the “Company”), a  biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that David Dodd, CEO…

Atlanta, GA, August 20, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it has entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 1,700,000 shares of the Company’s common stock (or common…

Company to Discuss Recent Mpox Developments as well as Milestones Related to the BARDA Project NextGen Award for Its Next-generation COVID-19 Vaccine   Atlanta, GA, August 15, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, is pleased to announce that it has been invited to…

Strategic Appointment Enhances GeoVax’s Leadership and Expertise in Vaccine Development   ATLANTA, GA, August 8, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the appointment of Teresa Lambe, PhD, OBE, FMedSci to its Scientific Advisory Board. Professor Lambe is the Calleva Head of…